Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia.
A patient from the Caribbean area with active T-cell lymphoma-leukaemia was primarily treated with deoxycoformycin (DCF), 5 mg/m2 i.v. on 3 consecutive days, followed by 5 mg/m2 i.v. weekly. A complete remission was attained and maintained during several weeks with DCF. A single consolidation course with other cytostatics was then given. The patient continues in complete remission without further therapy, 24 months after diagnosis, 17 months after the last cytostatic drugs. T-cell lymphoma-leukaemia has a bad prognosis with conventional anti-lymphoma therapy but was exquisitely sensitive to DCF in this patient.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003070:Coformycin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D017977:Deltaretrovirus; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D015649:Pentostatin; D012192:Retroviridae Infections / Q000188:drug therapy*; D012263:Ribonucleosides / Q000627:therapeutic use*; D013601:T-Lymphocytes
D000970:Antineoplastic Agents; D012263:Ribonucleosides; D003070:Coformycin; D015649:Pentostatin